[Small cell lung cancer: pathology and molecular pathology].
In the current WHO classification, together with the subtype of combined small cell lung cancer, small cell lung cancers (SCLC) are listed as a special tumour entity. Their microscopic appearance is characterised by small tumour cells with scant cytoplasm and frequently hypodiploid nuclei. For the precise histological diagnosis of SCLC, especially for the diagnostic differentiation from pulmonary NHL infiltrates, additional immunohistochemical investigations are recommended. The presented core classification of lung cancer is intended to facilitate the semi-quantitative registration of "atypical" SCLC. Genetically SCLC is especially characterised by manifold chromosomal deletions with losses of whole chromosomes or chromosome arms, associated with the inactivation of numerous tumour suppressor genes. Whereas the extensive DNA losses may explain the marked sensitivity of SCLC to anti-neoplastic chemotherapy or radiotherapy, its considerable chromosomal instability is correlated with the development of resistance to therapy.
Junker
K
K
Zentrum für Pathologie, Klinikum Bremen-Mitte, Bremen, Deutschland. klaus.junker@klinikum-bremen-mitte.de
Petersen
I
I
D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002877:Chromosomes, Human / Q000235:genetics; D005784:Gene Amplification; D006801:Humans; D007150:Immunohistochemistry; D015994:Incidence; D008175:Lung Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016019:Survival Analysis; D017741:Survivors